Consequence of Antivirals Versus Standard Care on Clinical Situation in Patients With COVID-19

{ 'indexed': {'date-parts': [[2024, 3, 19]], 'date-time': '2024-03-19T00:16:16Z', 'timestamp': 1710807376173}, 'reference-count': 20, 'publisher': 'Ovid Technologies (Wolters Kluwer Health)', 'issue': '2', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024, 3]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>Favipiravir and remdesivir have recently received more clinical interest ' 'for the management of COVID-19. The study aimed to explore the effectiveness of favipiravir ' 'or remdesivir on the clinical outcome of SARS-CoV-2 patients in comparison with standard ' 'care. All patients were given standard care before being randomized into the following 3 ' 'groups: standard care group (standard care only), remdesivir group (remdesivir and standard ' 'care), and favipiravir group (group 3, favipiravir and standard care). The primary endpoint ' 'of the study was time to recovery or the clinical condition of patients on day 14. A total of ' '156 patients underwent randomization (53 assigned to standard care group, 51 to favipiravir ' 'group, and 52 to remdesivir group). The percentage of death in favipiravir and remdesivir ' 'groups was higher than those in the standard care group and likewise the liver enzymes. ' 'Studying the time to starting therapy showed that early administration of antivirals resulted ' 'in lower percentage of mortality. The ratio of hazard for early favipiravir and remdesivir ' 'was lower in comparison with those treated with late administration of the same drugs (hazard ' 'ratio, 0.62; 95% confidence interval [CI], 0.62–0.73 vs 3.22; 95% CI, 3.21–3.44, ' 'respectively, for favipiravir and 0.11; 95% CI, 0.10–0.12 vs 3.44; 95% CI, 3.43–3.55, ' 'respectively, for remdesivir). For favipiravir or remdesivir to have more beneficial effects ' 'than standard care alone for SARS-CoV-2 patients, they need to be started as early as ' 'possible. However, regular monitoring of liver function is required.</jats:p>', 'DOI': '10.1097/ipc.0000000000001336', 'type': 'journal-article', 'created': {'date-parts': [[2024, 1, 10]], 'date-time': '2024-01-10T13:01:03Z', 'timestamp': 1704891663000}, 'page': '1-5', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Consequence of Antivirals Versus Standard Care on Clinical Situation in Patients With COVID-19', 'prefix': '10.1097', 'volume': '32', 'author': [ { 'given': 'Marwa N.', 'family': 'Alsaraj', 'sequence': 'first', 'affiliation': [{'name': 'Alshifaa Hospital, Nineveh Health Directorate'}]}, {'given': 'Mohannad E.', 'family': 'Qazzaz', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammed N.', 'family': 'Abed', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fawaz A.', 'family': 'Alassaf', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohanad A.', 'family': 'Alfahad', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mahmood H.M.', 'family': 'Jasim', 'sequence': 'additional', 'affiliation': []}], 'member': '276', 'published-online': {'date-parts': [[2024, 1, 8]]}, 'reference': [ { 'issue': '1', 'key': 'bib1-20240318', 'doi-asserted-by': 'crossref', 'first-page': '103', 'DOI': '10.1186/s13000-020-01017-8', 'article-title': 'Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and ' 'coronavirus disease 19 (COVID-19)—anatomic pathology perspective on ' 'current knowledge', 'volume': '15', 'year': '2020', 'journal-title': 'Diagn Pathol'}, { 'issue': '9', 'key': 'bib2-20240318', 'first-page': '4760', 'article-title': 'Compatibility of the ligand binding sites in the spike glycoprotein of ' 'COVID-19 with those in the aminopeptidase and the caveolins 1, 2 ' 'proteins', 'volume': '14', 'year': '2021', 'journal-title': 'Res J Pharm Technol'}, { 'issue': '12', 'key': 'bib3-20240318', 'doi-asserted-by': 'crossref', 'first-page': '1833', 'DOI': '10.1016/j.jiph.2020.07.014', 'article-title': 'COVID-19 and comorbidities: deleterious impact on infected patients', 'volume': '13', 'year': '2020', 'journal-title': 'J Infect Public Health'}, { 'issue': '2', 'key': 'bib4-20240318', 'doi-asserted-by': 'crossref', 'first-page': '228', 'DOI': '10.1016/j.jiph.2021.12.014', 'article-title': 'The SARS-CoV-2 mutations versus vaccine effectiveness: new ' 'opportunities to new challenges', 'volume': '15', 'year': '2022', 'journal-title': 'J Infect Public Health'}, { 'issue': '3', 'key': 'bib5-20240318', 'doi-asserted-by': 'crossref', 'first-page': '141', 'DOI': '10.1038/s41579-020-00459-7', 'article-title': 'Characteristics of SARS-CoV-2 and COVID-19', 'volume': '19', 'year': '2021', 'journal-title': 'Nat Rev Microbiol'}, { 'key': 'bib6-20240318', 'doi-asserted-by': 'crossref', 'first-page': '173348', 'DOI': '10.1016/j.ejphar.2020.173348', 'article-title': 'Update on therapeutic approaches and emerging therapies for SARS-CoV-2 ' 'virus', 'volume': '883', 'year': '2020', 'journal-title': 'Eur J Pharmacol'}, { 'key': 'bib7-20240318', 'first-page': '1', 'article-title': 'The journey of remdesivir: from Ebola to COVID-19', 'volume': '9', 'year': '2020', 'journal-title': 'Drugs Context'}, { 'issue': '4', 'key': 'bib8-20240318', 'doi-asserted-by': 'crossref', 'first-page': 'e2187', 'DOI': '10.1002/rmv.2187', 'article-title': 'Efficacy and safety of remdesivir in hospitalized Covid-19 patients: ' 'systematic review and meta-analysis including network meta-analysis', 'volume': '31', 'year': '2021', 'journal-title': 'Rev Med Virol'}, { 'key': 'bib9-20240318', 'doi-asserted-by': 'crossref', 'first-page': '111313', 'DOI': '10.1016/j.biopha.2021.111313', 'article-title': 'An update review of emerging small-molecule therapeutic options for ' 'COVID-19', 'volume': '137', 'year': '2021', 'journal-title': 'Biomed Pharmacother'}, { 'key': 'bib10-20240318', 'doi-asserted-by': 'crossref', 'first-page': '123', 'DOI': '10.1016/j.cegh.2020.07.011', 'article-title': 'Remdesivir and its antiviral activity against COVID-19: a systematic ' 'review', 'volume': '9', 'year': '2021', 'journal-title': 'Clin Epidemiol Glob Health'}, { 'key': 'bib11-20240318', 'doi-asserted-by': 'crossref', 'first-page': '501', 'DOI': '10.1016/j.ijid.2020.10.069', 'article-title': 'Role of favipiravir in the treatment of COVID-19', 'volume': '102', 'year': '2021', 'journal-title': 'Int J Infect Dis'}, { 'key': 'bib12-20240318', 'doi-asserted-by': 'crossref', 'first-page': '107512', 'DOI': '10.1016/j.pharmthera.2020.107512', 'article-title': 'Favipiravir, an anti-influenza drug against life-threatening RNA virus ' 'infections', 'volume': '209', 'year': '2020', 'journal-title': 'Pharmacol Ther'}, { 'issue': '1', 'key': 'bib13-20240318', 'doi-asserted-by': 'crossref', 'first-page': '4682', 'DOI': '10.1038/s41467-020-18463-z', 'article-title': 'Rapid incorporation of favipiravir by the fast and permissive viral RNA ' 'polymerase complex results in SARS-CoV-2 lethal mutagenesis', 'volume': '11', 'year': '2020', 'journal-title': 'Nat Commun'}, { 'key': 'bib14-20240318', 'doi-asserted-by': 'crossref', 'first-page': '8557', 'DOI': '10.2147/IJGM.S332458', 'article-title': 'Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for ' 'COVID-19 treatment: a systematic review', 'volume': '14', 'year': '2021', 'journal-title': 'Int J Gen Med'}, { 'issue': '19', 'key': 'bib15-20240318', 'doi-asserted-by': 'crossref', 'first-page': '1813', 'DOI': '10.1056/NEJMoa2007764', 'article-title': 'Remdesivir for the treatment of COVID-19—final report', 'volume': '383', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'issue': '11', 'key': 'bib16-20240318', 'doi-asserted-by': 'crossref', 'first-page': '1048', 'DOI': '10.1001/jama.2020.16349', 'article-title': 'Effect of remdesivir vs standard care on clinical status at 11 days in ' 'patients with moderate COVID-19', 'volume': '324', 'year': '2020', 'journal-title': 'JAMA'}, { 'issue': '7824', 'key': 'bib17-20240318', 'doi-asserted-by': 'crossref', 'first-page': '273', 'DOI': '10.1038/s41586-020-2423-5', 'article-title': 'Clinical benefit of remdesivir in rhesus macaques infected with ' 'SARS-CoV-2', 'volume': '585', 'year': '2020', 'journal-title': 'Nature'}, { 'key': 'bib18-20240318', 'doi-asserted-by': 'crossref', 'first-page': '290', 'DOI': '10.1016/j.ijid.2020.06.093', 'article-title': 'Case report study of the first five COVID-19 patients treated with ' 'remdesivir in France', 'volume': '98', 'year': '2020', 'journal-title': 'Int J Infect Dis'}, { 'issue': '9', 'key': 'bib19-20240318', 'doi-asserted-by': 'crossref', 'first-page': 'ofaa345', 'DOI': '10.1093/ofid/ofaa345', 'article-title': 'Remdesivir treatment for severe COVID-19 in third-trimester pregnancy: ' 'case report and management discussion', 'volume': '7', 'year': '2020', 'journal-title': 'Open Forum Infect Dis'}, { 'issue': '5', 'key': 'bib20-20240318', 'doi-asserted-by': 'crossref', 'first-page': '881', 'DOI': '10.1007/s12072-020-10077-3', 'article-title': 'Liver injury in remdesivir-treated COVID-19 patients', 'volume': '14', 'year': '2020', 'journal-title': 'Hepatol Int'}], 'container-title': 'Infectious Diseases in Clinical Practice', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://journals.lww.com/10.1097/IPC.0000000000001336', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 3, 18]], 'date-time': '2024-03-18T23:01:14Z', 'timestamp': 1710802874000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journals.lww.com/10.1097/IPC.0000000000001336'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 1, 8]]}, 'references-count': 20, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2024]]}}, 'URL': 'http://dx.doi.org/10.1097/IPC.0000000000001336', 'relation': {}, 'ISSN': ['1536-9943', '1056-9103'], 'subject': [], 'container-title-short': 'Infect Dis Clin Pract', 'published': {'date-parts': [[2024, 1, 8]]}}